Fármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafío!

dc.contributorTorres Dueñas, Diego [0000066885]
dc.contributorEspinosa Peña, Andrés Eduardo [0001356787]
dc.contributorNiño Mantilla, María Eugenia [0000535885]
dc.contributorCárdenas Angelone, María Eugenia [0000066761]
dc.contributorNiño Mantilla, María Eugenia [1R_FcOoAAAAJ]
dc.contributorTorres Dueñas, Diego [0000-0002-8006-7461]
dc.contributorEspinosa Peña, Andrés Eduardo [0000-0002-1584-7218]
dc.contributorAlarcón Forero, Laura Carolina [0000-0002-0610-1174]
dc.contributorNiño Mantilla, María Eugenia [0000-0003-2945-5175]
dc.contributorAlarcón Forero, Laura Carolina [Laura-Alarcon-Forero]
dc.contributorNiño Mantilla, María Eugenia [Maria-Nino-3]
dc.contributorGrupo de Investigación en Ciencias y Educación en Salud
dc.creatorTorres Dueñas, Diego
dc.creatorEspinosa Peña, Andrés Eduardo
dc.creatorAlarcón Forero, Laura Carolina
dc.creatorNiño Mantilla, María Eugenia
dc.creatorCárdenas Angelone, María Eugenia
dc.date.accessioned2020-10-27T14:20:38Z
dc.date.available2020-10-27T14:20:38Z
dc.date.created2020-10-27T14:20:38Z
dc.date.issued2010-04-11
dc.identifier2382-4603
dc.identifier0123-7047
dc.identifierhttp://hdl.handle.net/20.500.12749/10258
dc.identifierinstname:Universidad Autónoma de Bucaramanga UNAB
dc.identifierrepourl:https://repository.unab.edu.co
dc.description.abstractResumenLa sepsis ocupa el primer lugar entre las causas de mortalidad en las unidades de cuidado intensivo, razón por el cual su comprensión ha sido objetivo de múltiples estudios. Esta patologÍa representa un reto para el médico ya que sus criterios diagnósticos nunca han podido llegar a un consenso, dificultando asÍ su enfoque terapéutico.[Torres-Dueñas D, Espinosa AE, Alarcón LC, Niño ME, Cárdenas ME. Fármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafÍo!.Palabras clave: Sepsis, SÍndrome de respuesta inflamatoria sistémica, Mediadores de inflamación, Terapéutica.
dc.languagespa
dc.publisherUniversidad Autónoma de Bucaramanga UNAB
dc.publisherFacultad Ciencias de la Salud
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/440
dc.relationAngus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10
dc.relationBone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17:389–93.
dc.relationBone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-55.
dc.relationPoeze M, Ramsay G, Gerlach H, Rubulotta F, Levy M. An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care 2004; 8:R409–13.
dc.relationVincent JL. Dear Sirs, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372–4.
dc.relationJaimes F, Garcés J, Cuervo J, Ramírez F, Ramírez J, Vargas A, et al. The systemic inflammatory response syndrome (SIRS) to identify infected patients in the emergency room. Intensive Care Med 2003; 29:1368–71.
dc.relationCarlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: time to reconsider the concept. Crit Care Med 2008; 36:964-6.
dc.relationCalandra T, Cohen J. The International Sepsis ForumConsensus Conference on definitions of infection in the intensive care unit. Crit Care Med 2005; 33:1538–48.
dc.relationMarshall JC. Sepsis research: Where have we gone wrong? Crit Care Resusc 2006; 8:241-3.
dc.relationJaimes F. A literature review of the epidemiology of sepsis in Latin America. Rev Panam Salud Publica 2005; 18:163 71.
dc.relationMichalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980; 141:55-63.
dc.relationZiegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225–30.
dc.relationBeutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869–71.
dc.relationRemick DG. Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 2003; 9:75–82.
dc.relationPoltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in the Tir4 gene. Science 1998; 282:2085–88.
dc.relationSansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 2006; 7:1237-42.
dc.relationLiu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L622–L645.
dc.relationCasey LC, Balk RA, Bone RC. Plasma cytokines and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993: 119:771–8.
dc.relationCalvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032–37.
dc.relationDellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17–60.
dc.relationHauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B. Nitric Oxide Synthase Inhibition in Sepsis? Lessons Learned from Large-Animal Studies. Anesth Analg 2005; 101:488–98.
dc.relationTorres-Dueñas D, Benjamim CF, Ferreira SH, Cunha FQ. Failure of neutrophil migration to infectious focus and cardiovascular changes on sepsis in rats: effects of the inhibition of nitric oxide production, removal of infectious focus, and antimicrobial treatment. Shock 2006; 25:267
dc.relation(Suppl 1):107–19. 25. Alves-Filho JC, de Freitas A, Russo M, Cunha FQ. Toll-like receptor 4 signaling leads to neutrophil migration impairment in polymicrobial sepsis. Crit Care Med 2006; 34:461–70.
dc.relationAbraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998: 351:929–33.
dc.relationLopez A. Lorente JA, Steingrub J. Bakker J. McLuckie A. Willatts S, et al. Multiple-center, randomized, placebo controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21–30.
dc.relationHoesel LM, Neff TA, Neff SB, Younger JG, Olle EW, Gao H, et al. A. harmful and protective roles of neutrophils in sepsis. Shock 2005; 24:40–7.
dc.relationFierro IM, Nascimento-DaSilva V, Arruda MA, Freitas MS, Plotkowski MC, Cunha FQ, et al. Induction of NOS in rat blood PMM in vivo and in vitro: modulation by tyrosine kinase and involvement in bactericidal activity. J Leukoc Biol 1999; 65:508-14.
dc.relationMoncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
dc.relationMcGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br JAnaesth. 2007; 98:163-75.
dc.relationBernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
dc.relationEichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003; 31(Suppl 1):S94-6.
dc.relationGentry CA, Gross KB, Sud B, Drevets DA. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009;37:19–25.
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/440/422
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.sourceMedUNAB; Vol. 13 Núm. 1 (2010): Sepsis, Sedentarismo, Estado epiléptico; 13-16
dc.subjectCiencias de la salud
dc.subjectMedicina
dc.subjectCiencias médicas
dc.subjectCiencias biomédicas
dc.subjectCiencias de la vida
dc.subjectInnovaciones en salud
dc.subjectInvestigaciones
dc.titleFármaco-terapéutica de la sepsis: ¡un proceso frustrante y un gran desafío!


Este ítem pertenece a la siguiente institución